Protagenic Therapeutics (PTIX) Competitors $0.22 -0.02 (-7.82%) Closing price 04:00 PM EasternExtended Trading$0.22 0.00 (-0.40%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PTIX vs. NKGN, PTN, LIPO, BCLI, FRTX, GTBP, GNPX, ALBT, NLSP, and SNGXShould you be buying Protagenic Therapeutics stock or one of its competitors? The main competitors of Protagenic Therapeutics include NKGen Biotech (NKGN), Palatin Technologies (PTN), Lipella Pharmaceuticals (LIPO), Brainstorm Cell Therapeutics (BCLI), Fresh Tracks Therapeutics (FRTX), GT Biopharma (GTBP), Genprex (GNPX), Avalon GloboCare (ALBT), NLS Pharmaceutics (NLSP), and Soligenix (SNGX). These companies are all part of the "pharmaceutical products" industry. Protagenic Therapeutics vs. NKGen Biotech Palatin Technologies Lipella Pharmaceuticals Brainstorm Cell Therapeutics Fresh Tracks Therapeutics GT Biopharma Genprex Avalon GloboCare NLS Pharmaceutics Soligenix NKGen Biotech (NYSE:NKGN) and Protagenic Therapeutics (NASDAQ:PTIX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations. Which has more risk and volatility, NKGN or PTIX? NKGen Biotech has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Protagenic Therapeutics has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Does the MarketBeat Community prefer NKGN or PTIX? NKGen Biotech and Protagenic Therapeutics both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformNKGen BiotechN/AN/AProtagenic TherapeuticsN/AN/A Which has stronger earnings & valuation, NKGN or PTIX? Protagenic Therapeutics has lower revenue, but higher earnings than NKGen Biotech. Protagenic Therapeutics is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNKGen Biotech$80K71.41-$82.94M-$2.45-0.05Protagenic TherapeuticsN/AN/A-$5M-$1.13-0.20 Does the media favor NKGN or PTIX? In the previous week, Protagenic Therapeutics had 2 more articles in the media than NKGen Biotech. MarketBeat recorded 2 mentions for Protagenic Therapeutics and 0 mentions for NKGen Biotech. Protagenic Therapeutics' average media sentiment score of 0.22 beat NKGen Biotech's score of 0.00 indicating that Protagenic Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment NKGen Biotech Neutral Protagenic Therapeutics Neutral Is NKGN or PTIX more profitable? NKGen Biotech's return on equity of 0.00% beat Protagenic Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NKGen BiotechN/A N/A -479.36% Protagenic Therapeutics N/A -308.97%-228.73% Do institutionals & insiders have more ownership in NKGN or PTIX? 76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 8.0% of Protagenic Therapeutics shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by company insiders. Comparatively, 35.0% of Protagenic Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryProtagenic Therapeutics beats NKGen Biotech on 6 of the 11 factors compared between the two stocks. Get Protagenic Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTIX vs. The Competition Export to ExcelMetricProtagenic TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.69M$6.85B$5.55B$8.04BDividend YieldN/A2.95%5.09%4.22%P/E Ratio-0.187.5022.7518.82Price / SalesN/A257.30403.97106.68Price / CashN/A65.8538.1834.62Price / Book0.276.576.794.33Net Income-$5M$143.37M$3.22B$247.85M7 Day Performance2.71%3.64%2.30%2.73%1 Month Performance-1.37%6.02%3.64%3.38%1 Year Performance-82.78%-2.12%16.87%5.82% Protagenic Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTIXProtagenic Therapeutics0.8763 of 5 stars$0.22-7.8%N/A-81.3%$1.69MN/A-0.182Gap UpNKGNNKGen BiotechN/A$0.14+5.9%N/A-90.9%$6.07M$80,000.00-0.03N/AGap UpPTNPalatin TechnologiesN/A$0.23+5.0%N/AN/A$6.01M$350,000.00-0.1530Gap DownLIPOLipella Pharmaceuticals2.2512 of 5 stars$2.28-5.0%N/A-56.7%$5.81M$536,357.00-0.544Upcoming EarningsPositive NewsGap DownBCLIBrainstorm Cell Therapeutics3.7142 of 5 stars$0.86-1.8%$30.00+3,388.4%-82.2%$5.71MN/A-0.1840FRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+0.0%$5.59M$10.06M-0.6620GTBPGT Biopharma3.5203 of 5 stars$2.17-4.4%$11.00+406.9%-22.7%$5.50MN/A-0.318Short Interest ↓Positive NewsGap DownGNPXGenprex4.0333 of 5 stars$0.23-6.2%$10.00+4,342.5%-87.8%$5.44MN/A0.0020ALBTAvalon GloboCare1.0845 of 5 stars$3.23-9.5%N/A-11.0%$5.34M$1.31M-0.165Short Interest ↑NLSPNLS PharmaceuticsN/A$1.45-0.7%N/A+1,031.4%$5.22MN/A0.006SNGXSoligenix0.3146 of 5 stars$2.07-1.4%N/A-69.7%$5.20M$840,000.00-0.2720Upcoming Earnings Related Companies and Tools Related Companies NKGen Biotech Alternatives Palatin Technologies Alternatives Lipella Pharmaceuticals Alternatives Brainstorm Cell Therapeutics Alternatives Fresh Tracks Therapeutics Alternatives GT Biopharma Alternatives Genprex Alternatives Avalon GloboCare Alternatives NLS Pharmaceutics Alternatives Soligenix Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTIX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagenic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagenic Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PTIX Stock Free PTIX Stock Alerts